Speaker(s): 

Elena Marines, PharmD, BCACP, – Ambulatory Clinical Pharmacist, Medication Therapy Disease Management, Geisinger Multi-Specialty Clinic, Lewistown PA - has nothing to disclose.

Moderator(s): 

Adriene K. Zook, PharmD, RPH, - Manager Pharmacy, Geisinger Medication Therapy Disease Management, Danville PA - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Recognize increased risks associated with having diabetes.

• Identify medication(s) in sodium-glucose cotransporter 2 inhibitors (SGLT2) class.

• Identify medication(s) in glucagon-like peptide-1 (GLP-1)  receptor agonist class. 

• Identify medication(s) in glucose-dependent insulinotropic polypeptide (GIP)/Glucagon-Like Peptide (GLP-1) Receptor Agonist class. 

• Recognize appropriate and inappropriate patients for each above listed class.

• Investigate additional benefits associated with these classes.

• Familiarize yourself with Geisinger T2DM diabetes carepath

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Stacy Coolbaugh, MBA, RDN, LDN; Angela Esherick, RDN, LDN, CDCES; Adriene Zook, PharmD, RPH; Amy Luzier Barrett, RN, MSN, MEd, and Joey Underhill have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None